Literature DB >> 29326243

Concentrative Transport of Antifolates Mediated by the Proton-Coupled Folate Transporter (SLC46A1); Augmentation by a HEPES Buffer.

Rongbao Zhao1, Mitra Najmi1, Srinivas Aluri1, David C Spray1, I David Goldman2.   

Abstract

The proton-coupled folate transporter (PCFT) is ubiquitously expressed in solid tumors to which it delivers antifolates, particularly pemetrexed, into cancer cells. Studies of PCFT-mediated transport, to date, have focused exclusively on the influx of folates and antifolates. This article addresses the impact of PCFT on concentrative transport, critical to the formation of the active polyglutamate congeners, and at pH levels relevant to the tumor microenvironment. An HeLa-derived cell line was employed, in which folate-specific transport was mediated exclusively by PCFT. At pH 7.0, there was a substantial chemical gradient for methotrexate that decreased as the extracellular pH was increased. A chemical gradient was still detected at pH 7.4 in the usual HEPES-based transport buffer in contrast to what was observed in a bicarbonate/CO2-buffered medium. This antifolate gradient correlated with an alkaline intracellular pH in the former (pH 7.85), but not the latter (pH 7.39), buffer and was abolished by the protonophore carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone. The gradient in HEPES buffer at pH 7.4 was the result of the activity of Na+/H+ exchanger(s); it was eliminated by inhibitors of Na+/H+ exchanger (s) or Na+/K+ ATPase. An antifolate chemical gradient was also detected in bicarbonate buffer at pH 6.9 versus 7.4, also suppressed by carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone. When the membrane potential is considered, PCFT generates substantial transmembrane electrochemical-potential gradients at extracellular pH levels relevant to the tumor microenvironment. The augmentation of intracellular pH, when cells are in a HEPES buffer, should be taken into consideration in studies that encompass all proton-coupled transporter families.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29326243      PMCID: PMC5801552          DOI: 10.1124/mol.117.110445

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  38 in total

1.  Enteropathogenic Escherichia coli markedly decreases the resting membrane potential of Caco-2 and HeLa human epithelial cells.

Authors:  M A Stein; D A Mathers; H Yan; K G Baimbridge; B B Finlay
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 2.  The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption.

Authors:  Rongbao Zhao; Srinivas Aluri; I David Goldman
Journal:  Mol Aspects Med       Date:  2016-09-21

Review 3.  The proton-coupled folate transporter: physiological and pharmacological roles.

Authors:  Rongbao Zhao; I David Goldman
Journal:  Curr Opin Pharmacol       Date:  2013-12       Impact factor: 5.547

4.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

Review 5.  The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

Authors:  Yehuda G Assaraf
Journal:  Drug Resist Updat       Date:  2006-11-07       Impact factor: 18.500

6.  Inhibition of the proton-coupled folate transporter (PCFT-SLC46A1) by bicarbonate and other anions.

Authors:  Rongbao Zhao; Michele Visentin; Sylvia O Suadicani; I David Goldman
Journal:  Mol Pharmacol       Date:  2013-04-22       Impact factor: 4.436

7.  A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.

Authors:  Rongbao Zhao; Feng Gao; Marie Hanscom; I David Goldman
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

Review 8.  Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors.

Authors:  Rongbao Zhao; I David Goldman
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

Review 9.  The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29.

Authors:  James D Young; Sylvia Y M Yao; Jocelyn M Baldwin; Carol E Cass; Stephen A Baldwin
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

10.  The molecular mechanism of action of the proton ionophore FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone).

Authors:  R Benz; S McLaughlin
Journal:  Biophys J       Date:  1983-03       Impact factor: 4.033

View more
  2 in total

Review 1.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

2.  Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.

Authors:  Giovanna Li Petri; Btissame El Hassouni; Rocco Sciarrillo; Niccola Funel; Giulia Mantini; Eveline A Zeeuw van der Laan; Stella Cascioferro; Amir Avan; Paolo Andrea Zucali; Nadia Zaffaroni; Tonny Lagerweij; Barbara Parrino; Kees Smid; Marcello Deraco; Carlotta Granchi; Alicja Braczko; Ryszard T Smolenski; Larry H Matherly; Gerrit Jansen; Yehuda G Assaraf; Patrizia Diana; Jacqueline Cloos; Godefridus J Peters; Filippo Minutolo; Elisa Giovannetti
Journal:  Br J Cancer       Date:  2020-06-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.